Alpha lipoic acid combined with epalrestat: a therapeutic option for patients with diabetic peripheral neuropathy
Wang X, Lin H, Xu S, Jin Y
Published in Drug Design, Development and Therapy
Methodology
Systematic review and meta-analysis of 12 randomized controlled trials of alpha-lipoic acid 600 mg/day plus epalrestat versus epalrestat monotherapy.
Key Findings
Combined therapy increased the total effectiveness rate versus epalrestat alone (14 days RR 1.40, 95% CI 1.16-1.69).
Conclusions
Adding alpha-lipoic acid to epalrestat improves symptom response, though trials are small and regional.
Limitations
Mostly small regional trials; effectiveness-rate outcomes rather than validated pain scales.
Supplements Studied
Compared to epalrestat monotherapy, ALA 600 mg/d once a day (qd) combined with epalrestat 50 mg three times a day (tid) augmented the total effectiveness rate (14 days - risk ratio [RR]: 1.40, 95% CI: 1.16-1.69
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Not reported
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.